Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Receives $10M Equity Investment from Sanofi-Aventis

Premium

Regulus Therapeutics said this week that it has received a $10 million equity investment from Sanofi-Aventis as part of the companies' recently announced microRNA therapeutics alliance.

In June, Regulus announced that it had inked a deal giving Sanofi-Aventis the worldwide, exclusive rights to use its technology and know-how to discover, develop, and commercialize miRNA drugs, including a fibrosis treatment targeting miR-21 (GSN 6/34/2010).

“With the addition of $10 million from the Sanofi-Aventis equity investment, Regulus has to date raised $40 million from equity financings and over $58 million from strategic pharmaceutical alliances,” Garry Menzel, executive vice president of corporate development and finance at Regulus, said in a statement.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.